Company Profile: Gilead Sciences, Inc. (GILD)
GILD insider trades (13 months) →$167.47 −1.68% vs. previous close · Market cap $207.72B
Today's multi-factor rank: 446 of 461 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. With negative EPS a P/E means nothing, so it is not shown.
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. With negative EPS a P/E means nothing, so it is not shown.
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. With negative EPS a P/E means nothing, so it is not shown.
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Gilead Sciences, Inc. (GILD) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| 10-Q | 2026-10-30 | View filing ↗ |
| 8-K | 2026-10-29 | View filing ↗ |
| N-PX | 2026-08-26 | View filing ↗ |
| 10-Q | 2026-08-06 | View filing ↗ |
| 8-K | 2026-08-04 | View filing ↗ |
| 8-K | 2026-05-20 | View filing ↗ |
| 10-Q | 2026-05-07 | View filing ↗ |
| 8-K | 2026-05-04 | View filing ↗ |
| 8-K | 2026-04-28 | View filing ↗ |
| SC TO-T/A | 2026-04-17 | View filing ↗ |
Company and Executive Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Mr. Daniel Patrick O'Day | Chairman & CEO | 60 | 8.70M |
| Mr. Andrew D. Dickinson | Executive VP & CFO | 55 | 3.14M |
| Ms. Johanna Mercier | Chief Commercial & Corporate Affairs Officer | 55 | 3.44M |
| Dr. Dietmar P. Berger M.D., Ph.D. | Chief Medical Officer | 56 | 5.92M |
| Ms. Erin E. Burkhart | Senior VP, Controller & Chief Accounting Officer | 46 | - |
| Ms. Jacquie Ross C.F.A. | Senior Vice President of Treasury & Investor Relations | - | - |
| Ms. Keeley M. Cain Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | 50 | - |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | 49 | - |
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.